Carrier Screening Market Size - By Type (Expanded Carrier Screening, Targeted Disease Screening), By Technology (DNA Sequencing, PCR), By Medical Condition (Pulmonary Conditions, Neurological Conditions), By End-use (Hospitals), & Forecast, 2024 – 2032

Carrier Screening Market Size - By Type (Expanded Carrier Screening, Targeted Disease Screening), By Technology (DNA Sequencing, PCR), By Medical Condition (Pulmonary Conditions, Neurological Conditions), By End-use (Hospitals), & Forecast, 2024 – 2032

Carrier Screening Market Size

Carrier Screening Market size was valued at around USD 2 billion in 2023 and is anticipated to grow at a CAGR of over 13.1% between 2024 and 2032. Increasing awareness towards possibility of a genetic risks among couples, rise in adoption of cost-effective technologies for carrier screening, along with growing emphasis on early diagnosis of genetic diseases are expected to drive the industry growth over the forecast period.
 

People with specific ethnicities or geographic backgrounds are more prone to be at risk of specific disorders. For instance, the American College of Obstetricians and Gynecologists (ACOG) recommends carrier screenings to parents from certain ethnicity such as the French-Canadian or Cajun descent for Tay-Sachs disease. Moreover, rise in adoption of carrier screening procedures and surging consumer interest towards personalized medicines are other factors anticipated to propel the carrier screening market expansion.
 

Carrier screening is a genetic testing that involves testing a sample of saliva, blood, or tissue from inside of the cheek. It is used to determine whether a healthy person is a carrier of a genetic disease. The healthcare professionals highly recommend couples to get this test done to check if they are at risk of having an offspring who is affected by any type of genetic complication.
 

Carrier screening for genetic diseases is among the widely established part of preconception and prenatal care especially in the developed world. Though carrier screening tests has long history, the industry has relatively limited regulatory guidelines available for providers leading to inconsistent practices. For example, countries including U.S., UK, Australia, and Canada have different guidelines for screening of cystic fibrosis carriers during pregnancy. Further, high cost of tests and lack of skilled professionals are predicted to impede the product adoption rate, thereby hampering the market growth over the analysis period.
 

COVID-19 Impact

The recent outbreak of COVID-19 pandemic had a negative impact on the carrier screening market revenue in 2020. Several restrictions including nation-wide lockdowns were imposed across different countries globally to avoid the spread of the virus. The COVID-19 pandemic had affected the overall healthcare industry including genetic testing market. Numerous factors including closing down of laboratories, interruption of non-emergent medical services, demand and supply shortages, and supply chain disturbances, among other factors impacted the market revenue. One of the key factors contributed to market decline was the fact that genetic councillors were not recognized as healthcare providers during the initial period. Although, as the COVID-19 infection rate decreased the industry witnessed a rapid recovery and an incremental surge in the year-on-year growth trend in the following years.
 

Carrier Screening Market Trends

Increasing prevalence of genetic disorders, rise in maternal age resulting in pregnancy complications and increase in awareness level for presence of genetic risks in people with medical history are anticipated to augment the industry growth over the forecast timeframe. Owing to such factors, there is a growing need for proper, precise, and early diagnosis of genetic disorders among young couples in reproductive age group. Thus, if one or both the parents belong to certain ethnicities that are at high risk of genetic complications, the doctor may likely to recommend carrier screening for such couples.
 

Carrier Screening Market Analysis

Based on type, the carrier screening market is segmented into targeted disease carrier screening and expanded carrier screening. The expanded carrier screening segment accounted for majority revenue share in 2022 and is expected to reach around USD 3.7 billion in 2032. This is primarily attributed to the fact that it is used in screening of multiple genetic disorders irrespective of the person's ethnic background. Expanded carrier screening panels use different type of new high-throughput technologies such as microarrays and sequencing. Additionally, launch of novel products is further anticipated to boost the segmental growth.
 

Based on technology, the market is categorized into polymerase chain reaction, microarrays, DNA sequencing, and others. The DNA sequencing segment held the leading revenue share and was valued at around USD 637 million in 2022. Increasing adoption of advanced techniques such the next-generation sequencing (NGS) technology and chromosomal microarrays are among the primary growth drivers boosting the segmental progression. The NGS technology aid in understanding of whole-genome sequencing to detect gene complications. It further helps in understanding the genome, epigenome and transcriptome of the person undergoing screening test. Hence, the afore-mentioned variables are projected to fuel the market growth over the forecast period.
 

Based on medical condition, the market is segregated into hematological conditions, neurological conditions, pulmonary conditions, and others. Pulmonary conditions segment dominated the carrier screening market in terms of revenue and was valued at USD 679 million in 2022. Carrier screening is majorly used for detection of different pulmonary conditions primarily for cystic fibrosis. It is an inherited disease caused due to mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
 

Based on end-use, the carrier screening market is bifurcated into hospitals, reference laboratories, physician offices & clinics, and others. The hospitals segment held a significant revenue share in 2022 and is anticipated to witness healthy growth with a CAGR of 13.5% throughout the forecast period. Increase in availability of range of genetic testing services portfolio is among the key factor for growing preference of patient population towards hospitals. Additionally, increasing awareness level, availability, and adoption of advanced carrier screening technologies, rise in overall genetic disease prevalence, presence of well-trained and equipped healthcare personnel, is projected to boost the segmental sales.
 

North America region held the dominating revenue share in the global carrier screening market and is expected to reach over USD 2.3 billion in 2032. Increase in R&D spending for different genetic complications, availability of wide range of carrier screening products are projected to support the regional growth trend. Favorable demographic trends including presence of significant patient pool, demand for direct-to consumer genetic testing model, and high adoption rate for prenatal and new-born genetic testing in the U.S. is expected to boost the market growth. Additionally, presence of significant target population is among the key driving factor for regional development.
 

Carrier Screening Market Share

Few of the leading players operating in the carrier screening market include

• Fulgent Genetics Inc.
• Thermo Fisher Scientific Inc.
• BGI Genomics
• InVitae Corporation
• Quest Diagnostics Inc.
• Illumina Inc.
• Myriad Genetics, Inc.

The market is fragmented in nature, with leading players, regional and local companies, along with start-ups improving the industry competition. The leading market players are involved in strategic developments including novel product launch, research and development, collaborations, to improve their market positioning and revenue generating capabilities.
 

Carrier Screening Industry News

• In February 2023, Fulgent Genetics, Inc. launched its expanded carrier screening panel, New Beacon787. This panel includes a total of 787 genes related to autosomal recessive and X-linked conditions. Such developments are expected to boost the company's revenue generating prospects and improve its business presence.
   
• In June 2022, Kindbody, a U.S. based, fertility service provider announced the acquisition of Phosphorus Labs, a reference laboratory. This strategic development will add carrier screening and genetic testing capabilities in company's end-to-end care delivery model.
   

Carrier screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Type

• Expanded Carrier Screening
• Predesigned Panel Testing
• Customized Panel Testing 
• Targeted Disease Carrier Screening

By Technology

• DNA Sequencing
• Polymerase Chain Reaction
• Microarrays
• Others

By Medical Condition

• Pulmonary Conditions
• Hematological Conditions
• Neurological Conditions
• Others

By End-use

• Hospitals
• Reference Laboratories
• Physician Offices & Clinics
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Peru
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Israel
  • Iran